Resection Rate of Locally Advanced Pancreatic Cancer in Gemcitabine Plus Nab-paclitaxel versus FOLFIRINOX

Ripal Gandhi; Shahriar Sharif; Amer H. Zureikat; Paula M. Novelli; Charles D. Lopez; Adel Kardosh; Ki Y. Chung; Wesley B. Jones; Hassan Hatoum; Kenneth Lee Meredith; Emmanuel E. Zervos; Antonio Ucar

Resection Rate of Locally Advanced Pancreatic Cancer in Gemcitabine Plus Nab-paclitaxel versus FOLFIRINOX

Ripal Gandhi, Shahriar Sharif, Amer H. Zureikat, Paula M. Novelli, Charles D. Lopez, Adel Kardosh, Ki Y. Chung, Wesley B. Jones, Hassan Hatoum, Kenneth Lee Meredith, Emmanuel E. Zervos, Antonio Ucar

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Clinical Oncology
Volume	39
State	Published - 2021

Disciplines

Medicine and Health Sciences

Cite this

@article{fc5f304d8c1d44ac93b6fc6ebc972ff4,

title = "Resection Rate of Locally Advanced Pancreatic Cancer in Gemcitabine Plus Nab-paclitaxel versus FOLFIRINOX",

author = "Ripal Gandhi and Shahriar Sharif and Zureikat, {Amer H.} and Novelli, {Paula M.} and Lopez, {Charles D.} and Adel Kardosh and Chung, {Ki Y.} and Jones, {Wesley B.} and Hassan Hatoum and Meredith, {Kenneth Lee} and Zervos, {Emmanuel E.} and Antonio Ucar",

note = "381 Background: There is no established treatment for locally advanced pancreatic cancer (LAPC), but by utilizing the regimens approved for metastatic pancreatic cancer, hope remains for rendering tumors resectable with chemotherapy. In this context, we looked at the resection rate in patients receiving gemcitabine plus nab-paclitaxel (Gem-Nab) in a prospective trial of patients with LAPC.",

year = "2021",

language = "American English",

volume = "39",

journal = "Journal of Clinical Oncology",

}

TY - JOUR

T1 - Resection Rate of Locally Advanced Pancreatic Cancer in Gemcitabine Plus Nab-paclitaxel versus FOLFIRINOX

AU - Gandhi, Ripal

AU - Sharif, Shahriar

AU - Zureikat, Amer H.

AU - Novelli, Paula M.

AU - Lopez, Charles D.

AU - Kardosh, Adel

AU - Chung, Ki Y.

AU - Jones, Wesley B.

AU - Hatoum, Hassan

AU - Meredith, Kenneth Lee

AU - Zervos, Emmanuel E.

AU - Ucar, Antonio

N1 - 381 Background: There is no established treatment for locally advanced pancreatic cancer (LAPC), but by utilizing the regimens approved for metastatic pancreatic cancer, hope remains for rendering tumors resectable with chemotherapy. In this context, we looked at the resection rate in patients receiving gemcitabine plus nab-paclitaxel (Gem-Nab) in a prospective trial of patients with LAPC.

PY - 2021

Y1 - 2021

UR - https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.3_suppl.381

M3 - Article

VL - 39

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -

Resection Rate of Locally Advanced Pancreatic Cancer in Gemcitabine Plus Nab-paclitaxel versus FOLFIRINOX

Disciplines

Other files and links

Cite this